000			01617 a2200433 4500
005			20250516023305.0
264		0	_c20110531
008			201105s 0 0 eng d
022			_a1756-185X
024	7		_a10.1111/j.1756-185X.2010.01592.x _2doi
040			_aNLM _beng _cNLM
100	1		_aEfthimiou, Petros
245	0	0	_aRituximab and lupus interstitial lung disease: friend or foe? _h[electronic resource]
260			_bInternational journal of rheumatic diseases _cFeb 2011
300			_ae3-4 p. _bdigital
500			_aPublication Type: Case Reports; Letter
650	0	4	_aAdult
650	0	4	_aAntibodies, Monoclonal, Murine-Derived _xtherapeutic use
650	0	4	_aAntirheumatic Agents _xtherapeutic use
650	0	4	_aDrug Therapy, Combination
650	0	4	_aDyspnea _xdrug therapy
650	0	4	_aGlucocorticoids _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aHydroxychloroquine _xtherapeutic use
650	0	4	_aImmunologic Factors _xtherapeutic use
650	0	4	_aLung Diseases, Interstitial _xdrug therapy
650	0	4	_aLupus Erythematosus, Systemic _xcomplications
650	0	4	_aMale
650	0	4	_aMycophenolic Acid _xanalogs & derivatives
650	0	4	_aPrednisolone _xtherapeutic use
650	0	4	_aRespiratory Function Tests
650	0	4	_aRituximab
650	0	4	_aSjogren's Syndrome _xcomplications
650	0	4	_aTreatment Outcome
700	1		_aKukar, Manil
700	1		_aHersh, Alissa
773	0		_tInternational journal of rheumatic diseases _gvol. 14 _gno. 1 _gp. e3-4
856	4	0	_uhttps://doi.org/10.1111/j.1756-185X.2010.01592.x _zAvailable from publisher's website
999			_c20581576 _d20581576